Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Atherosclerosis Therapeutics

Background:

• Atherosclerosis affects millions globally, with current therapies like statins having limitations in achieving optimal low-density lipoprotein-cholesterol (LDL-C) levels in many patients.
• Existing treatments for coronary heart disease (CHD) necessitate improved lipid-lowering strategies.
• Enhancing high-density lipoprotein (HDL) function presents a promising research direction for atherosclerosis treatment.

Purpose of the Study:

• To review the atheroprotective potential of in vitro synthesized reconstituted HDL particles with apolipoprotein E (apoE) as the sole apolipoprotein (rHDL-apoE).
• To summarize the atheroprotective properties of native HDL and its components, apolipoprotein A-I (apoA-I) and apoE.
• To explore the therapeutic potential of HDL-apoE and rHDL-apoE in combating atherosclerosis.

Main Methods:

• Review of existing literature on native HDL, apolipoproteins (apoA-I and apoE), and reconstituted HDL (rHDL) particles.
• Analysis of studies on rHDL-apoA-I and apoA-I-containing HDL from transgenic mice.
• Examination of recent developments concerning HDL-apoE and rHDL-apoE formulations.

Main Results:

• Native HDL and its apolipoproteins (apoA-I, apoE) possess atheroprotective properties.
• rHDL-apoA-I and apoA-I-containing HDL demonstrate anti-atherogenic functions.
• Novel rHDL formulations incorporating apoE (rHDL-apoE) exhibit potential for enhanced biological functions.

Conclusions:

• rHDL-apoE particles represent a novel therapeutic strategy for atherosclerosis.
• These novel formulations may offer improved efficacy compared to existing treatments.
• Further research into rHDL-apoE holds significant promise for future lipid-lowering therapies.